Jazz Pharmaceuticals (NASDAQ:JAZZ) CEO Renee Gala Sells 2,000 Shares of Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Renee Gala sold 2,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $243.03, for a total transaction of $486,060.00. Following the sale, the chief executive officer directly owned 143,394 shares of the company’s stock, valued at $34,849,043.82. The trade was a 1.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $240.48 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The company’s 50-day moving average price is $249.32 and its 200-day moving average price is $223.57. Jazz Pharmaceuticals PLC has a twelve month low of $123.88 and a twelve month high of $266.38. The company has a market cap of $15.61 billion, a P/E ratio of 16.58, a P/E/G ratio of 0.22 and a beta of 0.36.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The company’s revenue for the quarter was up 15.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($8.25) earnings per share. On average, sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 21.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on JAZZ shares. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, June 9th. Stifel Nicolaus set a $275.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Morgan Stanley lifted their price objective on shares of Jazz Pharmaceuticals from $283.00 to $322.00 and gave the company an “overweight” rating in a report on Wednesday, August 26th. Weiss Ratings upgraded shares of Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Finally, Canaccord Genuity Group set a $300.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $285.50.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Triumph Capital Management grew its holdings in Jazz Pharmaceuticals by 2.0% during the 2nd quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company’s stock worth $626,000 after acquiring an additional 52 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 0.3% in the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock valued at $4,228,000 after purchasing an additional 73 shares in the last quarter. UMB Bank n.a. lifted its position in shares of Jazz Pharmaceuticals by 12.6% during the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 81 shares during the last quarter. Pinnacle Associates Ltd. lifted its position in shares of Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after purchasing an additional 83 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC grew its stake in Jazz Pharmaceuticals by 4.4% in the first quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock worth $377,000 after purchasing an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.